Myeloma Crowd Radio

Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.



      episode 2: Myeloma Crowd Radio: William Matsui, MD, Johns Hopkins University

      Allogeneic stem cell transplant was the first ever immunotherapy available for mulitple myeloma patients. Dr. Matsui shares how the Johns Hopkins allo transplant procedure has significantly improved safety concerns. His research is now focused on extending and deepening remissions with a new immunotherapy antibody given with transplant. Dr. Matsui will also share his latest research on precursor myeloma cells (called myeloma stem cells) and how they can be targeted before growing into full ...



      Myeloma Crowd Radio: Martin Kaiser, MD, The Institute of Cancer Research, UK

      Dr. Martin Kaiser joins Myeloma Crowd Radio to share more about the latest advances in myeloma treatment in the United Kingdom and how the use of myeloma genomic data with thousands of patients in the UK is furthering new insights in myeloma care.    Thanks to our episode sponsor, SparkCures. SparkCures provides an easy way to find and join multiple myeloma clinical trials. 



      episode 1: Myeloma Crowd Radio: Robert Orlowski, MD, PhD, MD Anderson Cancer Center

      The year 2018 promises to be an exciting one in multiple myeloma research. Learn what about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. With the explosion of immunotherapy and combination approaches now in the clinic and in clinical trials,  the choices are greatly expanding for myeloma patients. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the ...



      episode 1: Myeloma Crowd Radio: Diahanna Valentine, Critical Care Financial Consulting

      Multiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to myeloma patients in this informative. show.  Diahanna is Owner and Founder of Critical Care Financial Consulting, LLC which takes a holistic approach to managing your finances in the face of a critical or chronic illness. She is an 18+ year Financial Advisor, ...



      Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber

      Myeloma patients can't wait until blood-based "liquid biopsies" replace the dreaded bone marrow biopsy. Painful and intrusive, the bone marrow biopsy is today's "standard" of myeloma testing to determine levels of myeloma disease burden in patients. These biopsies need to be performed at diagnosis, relapse and repeated every so often to determine response to treatment. Researchers at the Dana Farber Cancer Institute and the Harvard School of Medicine are creating a blood-based test that ...



      Myeloma Crowd Radio: Michael O'Dwyer, MD, National University of Ireland

      Sugar molecules could act as a smoke screen for multiple myeloma cells, essentially hiding them from the immune system.  The surface sugars, called sialic acids, can mark the cancer cells as “self” cells, giving the immune system the signal to ignore them.  Dr. Michael O'Dwyer is Director of the Blood Cancer Network Ireland and Professor of Hematology at the National University of Ireland Galway. Dr. O'Dwyer has expertise in the glycosylation process as it relates to multiple myeloma. The gl...



      Myeloma Crowd Radio: Sagar Lonial, MD, Winship Cancer Institute

      The recent meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) occurred recently in May and June. There are a wealth of updates on up-and-coming therapies, use of combinations to improve outcomes, strategies to reduce side effects and much more from myeloma specialists across the world.  Dr. Sagar Lonial will join us to share an overview of the major themes in myeloma advances from his leading-edge perspective. Dr. Sagar Lonial is an ...



      Myeloma Crowd Radio: Drs. Anja Seckinger and Dirk Hose, University of Heidelberg

      Many patients are familiar with the monoclonal antibodies daratumumab and elotuzumab. These target a specific protein on the surface of myeloma cells. A new approach is in progress to target both a protein on the surface of myeloma cells (BCMA) while also activating the immune system's T cells. This is called a bi-specific antibody, going after two targets at the same time. Join us to learn more about this fascinating approach from German researchers Anja Seckinger, MD and Dirk Hose, MD of ...



      Myeloma Crowd Radio: Elisabet Manasanch, MD, MD Anderson Cancer Center

      Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely to progress and is thus most likely to receive treatment. Dr. Manasanch is also studying the new monoclonal antibody Isatuximab in a clinical trial...



      Myeloma Crowd Radio: Dr. Guido Tricot, MD, PhD, University of Iowa

      Today's myeloma therapy can help patients gain remission, but the combinations can cause their own side effects because they target normal cells as well as cancer cells. Investigators at the University of Iowa including Dr. Guido Tricot and Dr. Frank Zhan have tested mega-doses of Vitamin C in combination with the standard chemo melphalan and found that the Vitamin C can kill myeloma cells while not affecting normal cells. Additionally, it boosts the power of melphalan, so that melphalan can...